EyePoint, Inc. Common Stock
$3.85
-$0.14 (-3.51%)
$3.77Day Range$4.06
Key Statistics
Market Cap
$331.92M
Shares Outstanding
86.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 27, 2005
Round Lot
100
Locale
US
Trading Data
Day Open
$3.95
Day High
$4.06
Day Low
$3.77
Volume
7.27M
VWAP
$3.91
Prev Close
$3.99
Transactions
--
Acc. Volume
--
About EyePoint, Inc. Common Stock
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
LABORATORY ANALYTICAL INSTRUMENTSSIC 3826214 employees480 PLEASANT STREET, WATERTOWN, MA, 02472617-926-5000IPO Jan 27, 2005US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001314102
- Composite FIGI
- BBG000F90JX5
- Share Class FIGI
- BBG001SNLCD2
- Ticker Root
- EYPT
- SIC Code
- 3826
About EyePoint, Inc. Common Stock (EYPT) Stock
EyePoint, Inc. Common Stock (EYPT) closed the 2026-09-18 session at $3.85, down 3.51% versus the previous close (-0.14). The stock opened at $3.95 and traded between $3.77 and $4.06 during that session. Session trading volume was 7.3M shares. The volume-weighted average price (VWAP) is $3.91.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
EyePoint, Inc. Common Stock has a market capitalization of $331.9 million. The company operates in the LABORATORY ANALYTICAL INSTRUMENTS industry classification. EYPT is listed on the XNAS exchange. The company employs approximately 214 people. EyePoint, Inc. Common Stock is headquartered in WATERTOWN, MA. The recorded listing date is 2005-01-27.
On this page you can find market EYPT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the LABORATORY ANALYTICAL INSTRUMENTS sector.